Skip to main content

Table 1 MYCN P44L and MAX R60Q mutation frequency in clinical and histological subgroups

From: MYCN and MAX alterations in Wilms tumor and identification of novel N-MYC interaction partners as biomarker candidates

 

Clinical data

Histology*

Total cases*

Low-risk

Intermediate-risk

High-risk

Metasatic relapse

Local relapse

Relapse (any)

Death

Compl. necrotic

Epithelial

Stromal

Mixed

Regressive

Focal anaplasia

Blastemal, primary surgery

Blastemal

Diffuse Anaplasia

MYCN P44L

4/85

6/55 #

7/108 §

3/44

0/31

3/81

1/80

6/231

9/267

0/15

1/25

4/61

0/34

24/810

(%)

4.7%

10.9%

6.5%

6.8%

–

3.7%

1.3%

2.6%

3.4%

–

4.0%

6.6%

–

3.0%

MAX R60Q

2/77

2/51

3/99 §

1/40

0/30

0/80

0/77

2/225

4/255

0/15

0/24

1/57

0/34

7/782

(%)

2.6%

3.9%

3.0%

2.5%

–

–

–

0.9%

1.6%

–

–

1.8%

–

0.9%

  1. *825 (MYCN P44L) and 797 (MAX R60Q) tumors from 810 and 782 cases, respectively. For 15 bilateral cases both histotypes were assessed
  2. # p = 0.005; §p < 0.05 (two-tailed Fisher's exact test)
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us